EQ
Equillium, Inc. Common Stock
stockNASDAQ
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.68 | 2026-09-28 | -16.96% | -7.426 |
| 1M | 2.21 | 2026-09-04 | -36.88% | -1.502 |
| 3M | 2.77 | 2026-07-06 | -49.64% | -0.283 |
| 6M | 2.01 | 2026-04-06 | -30.60% | 1.074 |
| 1Y | 1.50 | 2025-10-06 | -7.00% | 1.167 |
| 2Y | 0.86 | 2024-10-04 | +61.31% | — |
| 5Y | 6.99 | 2021-10-05 | -80.04% | 0.705 |
Equillium, Inc. Common Stock (NASDAQ:EQ) stock price today is $1.40, and today's volume is 934,794. EQ is down 9.416% today. The 30 day average volume is 619,020. EQ market cap is $88.45M with 63.41M shares outstanding.